CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 308, Issue 2, 2015, Pages E97-E110

  Chen, Guangzhi ^a   Renfan, Xu ^a   Zhang, Shasha ^a   Wang, Yinna ^a   Wang, Peihua ^a   Edin, Matthew L ^b   Zeldin, Darryl C ^b   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

CYP2J2; EETs; Inflammation; Nonalcoholic fatty liver disease; Oxidative stress; Palmitic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CATALASE; CYTOCHROME P450 2J2; CYTOKINE; EPOXYICOSATRIENOIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; MESSENGER RNA; PALMITIC ACID; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; ARACHIDONATE EPOXYGENASE; CYTOCHROME P450; DIHOMO GAMMA LINOLENIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; ELISA KIT; ENZYME ASSAY; FATTY LIVER; GENE EXPRESSION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LIPID DIET; LIPID LIVER LEVEL; LIPID PEROXIDATION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; ENZYMOLOGY; GENETICS; MALE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

8,11,14-EICOSATRIENOIC ACID; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CATALASE; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GLUTATHIONE PEROXIDASE; HEP G2 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PALMITIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; TRIGLYCERIDES;

EID: 84964693894     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00366.2014     Document Type: Article

References (46)

1. Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 141: 603–610, 2011.
2. Abraham NG, Sodhi K, Silvis AM, Vanella L, Favero G, Rezzani R, Lee C, Zeldin DC, Schwartzman ML. CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. Hypertension 64: 1352–1361, 2014.
3. Bai J, Rodriguez AM, Melendez JA, Cederbaum AI. Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury. J Biol Chem 274: 26217–26224, 1999.
4. Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 40: 776–780, 2007.
5. Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, Beilfuss A, Schmitt J, Hannivoort RA, Rust C, Berr F, Tschopp O, Gerken G, Friedman SL, Geier A, Canbay A. Free fatty acids repress SHP activation and adiponectin counteracts bile acid induced liver injury in super-obese patients with NASH. Hepatology 57: 1394–1406, 2013.
6. Chen G, Wang P, Zhao G, Xu G, Gruzdev A, Zeldin DC, Wang DW. Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice. Prostaglandins Other Lipid Mediators 96: 63–71, 2011.
7. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 21: 702–707, 2005.
8. Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E, Szabo G. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 300: G433–G441, 2011.
9. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastro-enterology 142: 711–725 e716, 2012.
10. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterol-ogy 114: 842–845, 1998.
11. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129: 1663– 1674, 2005.
12. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, DeGraff LM, Lih FB, Foley J, Bradbury JA, Graves JP, Tomer KB, Falck JR, Zeldin DC, Lee CR. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 25: 703–713, 2011.
13. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40: 185–194, 2004.
14. Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 15: 1325–1365, 2011.
15. Gao Y, Feng J, Ma K, Zhou Z, Zhu Y, Xu Q, Wang X. 8,9-Epoxyeicosatrienoic acid inhibits antibody production of B lymphocytes in mice. PLoS One 7: e40258, 2012.
16. Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione: hep-atocellular survival-death switch. J Gastroenterol Hepatol 21, Suppl 3: S3–S6, 2006.
17. Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, Scott DK, O’Doherty RM. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 59: 347–357, 2010.
18. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in nonalcoholic steatohepatitis. Clin Chim Acta 412: 1297–1305, 2011.
19. Kotzka J, Knebel B, Haas J, Kremer L, Jacob S, Hartwig S, Nitzgen U, Muller-Wieland D. Preventing phosphorylation of sterol regulatory element-binding protein 1a by MAP-kinases protects mice from fatty liver and visceral obesity. PLoS One 7: e32609, 2012.
20. Laurent A, Nicco C, Tran Van Nhieu J, Borderie D, Chereau C, Conti F, Jaffray P, Soubrane O, Calmus Y, Weill B, Batteux F. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 39: 1277–1285, 2004.
21. Li L, Chen L, Hu L, Liu Y, Sun HY, Tang J, Hou YJ, Chang YX, Tu QQ, Feng GS, Shen F, Wu MC, Wang HY. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 54: 1620–1630, 2011.
22. Liu L, Chen C, Gong W, Li Y, Edin ML, Zeldin DC, Wang DW. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther 339: 451–463, 2011.
23. Liu Y, Dang H, Li D, Pang W, Hammock BD, Zhu Y. Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice. PLoS One 7: e39165, 2012.
24. Matsuzaka T, Atsumi A, Matsumori R, Nie T, Shinozaki H, Suzuki-Kemuriyama N, Kuba M, Nakagawa Y, Ishii K, Shimada M, Kobayashi K, Yatoh S, Takahashi A, Takekoshi K, Sone H, Yahagi N, Suzuki H, Murata S, Nakamuta M, Yamada N, Shimano H. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology 56: 2199–2208, 2012.
25. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 30: 158–162, 2012.
26. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am J Resp Cell Mol Biol 38: 192–201, 2008.
27. Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, Kumar M, Hughes WM Jr, Metreveli N, Rosenberger DS, Singh M, Vacek TP, Rodriguez WE, Ayotunde A, Tyagi SC. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. J Cell Physiol 215: 771–781, 2008.
28. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276–1279, 1999.
29. Oz HS, Im HJ, Chen TS, de Villiers WJ, McClain CJ. Glutathioneenhancing agents protect against steatohepatitis in a dietary model. J Biochem Mol Toxicol 20: 39–47, 2006.
30. Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 55: 1369–1378, 2012.
31. Potente M, Michaelis UR, Fisslthaler B, Busse R, Fleming I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem 277: 15671–15676, 2002.
32. Rabelo F, Oliveira CP, Faintuch J, Mazo DF, Lima VM, Stefano JT, Barbeiro HV, Soriano FG, Alves VA, Carrilho FJ. Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis. Obes Surg 20: 906–912, 2010.
33. Rajesh M, Mukhopadhyay P, Batkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horvath B, Mukhopadhyay B, Becker L, Hasko G, Liaudet L, Wink DA, Veves A, Mechoulam R, Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 56: 2115–2125, 2010.
34. Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 99: 1708–1717, 2004.
35. Robinson SM, Mann DA. Role of nuclear factor kappaB in liver health and disease. Clin Sci (Lond) 118: 691–705, 2010.
36. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 52: 59–69, 2012.
37. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43: 163–172, 2006.
38. Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 49: 87–96, 2009.
39. Skepner JE, Shelly LD, Ji C, Reidich B, Luo Y. Chronic treatment with epoxyeicosatrienoic acids modulates insulin signaling and prevents insulin resistance in hepatocytes. Prostaglandins Other Lipid Mediators 94: 3–8, 2011.
40. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7: 456–465, 2011.
41. Vaidyanathan V, Bastarrachea RA, Higgins PB, Voruganti VS, Kamath S, DiPatrizio NV, Piomelli D, Comuzzie AG, Parks EJ. Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates. Am J Physiol Endocrinol Metab 303: E624–E634, 2012.
42. Valle A, Catalan V, Rodriguez A, Rotellar F, Valenti V, Silva C, Salvador J, Fruhbeck G, Gomez-Ambrosi J, Roca P, Oliver J. Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects. Liver Int 32: 951–961, 2012.
43. Videla LA, Tapia G, Rodrigo R, Pettinelli P, Haim D, Santibanez C, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Castillo J, Korn O, Maluenda F, Diaz JC, Rencoret G, Poniachik J. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring) 17: 973–979, 2009.
44. Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol 23: 345–352, 2012.
45. Zhao G, Wang J, Xu X, Jing Y, Tu L, Li X, Chen C, Cianflone K, Wang P, Dackor RT, Zeldin DC, Wang DW. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-alpha-induced injury. J Lipid Res 53: 456–466, 2012.
46. Zheng C, Wang L, Li R, Ma B, Tu L, Xu X, Dackor RT, Zeldin DC, Wang DW. Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am J Resp Cell Mol Biol 43: 740–749, 2010.